Moderately Hypofractionated Online Adaptive Radiotherapy for Cervical Cancer: A Prospective Study of Feasibility, Acute Toxicity and Dosimetric Benefits
Cancers · 04.08.2026 · 18 (15) · 2493
DOI: 10.3390/cancers18152493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 04.08.2026. Verfasst von Zheng Zeng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Sh…. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, Ministry of Science and Technology of the People's Re-public of China, National High Level Hospital Clinical Research Funding, National Key R&D Program of China, Ministry of Science and Technology of the People’s Republic of China.
Abstract (Originalsprache)
Background/Objectives: Moderately hypofractionated radiotherapy (MHRT) may shorten treatment duration for cervical cancer but raises concerns regarding toxicity due to substantial interfractional pelvic organ motion. This prospective study evaluated the feasibility, workflow efficiency, dosimetric benefits, and acute toxicities of daily online adaptive radiotherapy (oART)-guided MHRT.
Methods
Thirty patients with FIGO 2018 stage IB1–IIB or IIIC1 cervical squamous cell carcinoma receiving definitive chemoradiotherapy were prospectively included between September 2023 and April 2024 (NCT05994300). All patients underwent daily oART, receiving 43.35 Gy in 17 fractions to the pelvic target volume, with a simultaneous integrated boost to 54.40 Gy in 17 fractions for involved lymph nodes. The adaptive workflow consisted of iterative cone-beam computed tomography acquisition, artificial intelligence-assisted contouring, physician review, plan adaptation, and treatment verification. Workflow efficiency, plan selection, target coverage, organ-at-risk (OAR) sparing, treatment completion, early tumor response and acute toxicity were prospectively assessed.
Results
A total of 510 adaptive fractions were delivered. The first-attempt adaptation success rate was 99.0%, and adapted plans were selected in 99.4% of fractions. The mean adaptive workflow and total treatment times were 17.3 and 23.3 min per fraction, respectively. Compared with scheduled plans, adapted plans significantly improved target coverage, with V100% increasing by 7.26% for the planning target volume of the uterus and 8.79% for planning target volume of the cervix (both p < 0.001), while significantly reducing doses to the bladder, rectum, small bowel, bone marrow, and femoral heads. All patients achieved complete clinical response at 3 months. Acute toxicity was generally manageable; Grade ≥ 3 gastrointestinal, genitourinary, and hematologic toxicities occurred in 10%, 0%, and 40% of patients, respectively, including one Grade 4 neutropenia event, and no treatment interruptions.
Conclusions
Daily oART-guided MHRT was feasible and efficient, providing improved target coverage and reduced OAR doses compared with scheduled plans. Acute toxicity was acceptable. These findings provide early prospective evidence supporting the feasibility of this treatment strategy and warrant further validation in larger prospective studies with longer follow-up.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing 100730, China.
- Eight-Year Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Department of Radiation Oncology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan Wa…
ORCID-Profile: Junfang Yan, Ke Hu, Fuquan Zhang
Förderung
- National Key R&D Program of China, Ministry of Science and Technology of the People's Re-public of China
- National High Level Hospital Clinical Research Funding
- National Key R&D Program of China, Ministry of Science and Technology of the People’s Republic of China
Zitieren
APA
Zeng, Z., Chen, Y., Meng, X., Sun, Y., Yan, J., Hu, K., & Zhang, F. (2026). Moderately Hypofractionated Online Adaptive Radiotherapy for Cervical Cancer: A Prospective Study of Feasibility, Acute Toxicity and Dosimetric Benefits. Cancers, 18(15), 2493. https://doi.org/10.3390/cancers18152493
Vancouver
Zeng Z, Chen Y, Meng X, Sun Y, Yan J, Hu K, et al. Moderately Hypofractionated Online Adaptive Radiotherapy for Cervical Cancer: A Prospective Study of Feasibility, Acute Toxicity and Dosimetric Benefits. Cancers. 2026;18(15):2493. doi:10.3390/cancers18152493
BibTeX
@article{Zeng2026,
author = {Zeng, Zheng and Chen, Yining and Meng, Xiangyin and Sun, Yuliang and Yan, Junfang and Hu, Ke and Zhang, Fuquan},
title = {Moderately Hypofractionated Online Adaptive Radiotherapy for Cervical Cancer: A Prospective Study of Feasibility, Acute Toxicity and Dosimetric Benefits},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2493},
doi = {10.3390/cancers18152493}
}
EUVIMED